Additionally, SGLT2 inhibitors are known to reduce uric acid levels in patients with diabetes and/or heart failure [10–14], yet randomised clinical trial evidence in patients with CKD is lacking. This evidence concerns the gene SLC5A2 and chronic kidney disease.